Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  CANADIAN NATIONAL STOCK EXCHANGE  >  FSD Pharma Inc    HUGE   CA35954B1076

FSD PHARMA INC

(HUGE)
My previous session
Most popular
SummaryQuotesChartsNewsCompany 
News SummaryMost relevantAll newsOfficial PublicationsSector news

FSD Pharma : Announces Holdings in Cannara Biotech Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 05:27pm EDT

TORONTO, Jan. 11, 2019 /CNW/ - FSD Pharma ("FSD") announced today that, in connection with the business combination (the "Business Combination") completed on December 31, 2018 among Cannara Biotech Inc. (formerly, Dunbar Capital Corp.) (the "Issuer"), Cannara Biotech Inc. and 11038427 Canada Inc., FSD Pharma, directly or indirectly, acquired ownership of 85,003,750 common shares ("Common Shares") of the Issuer, representing 12.25% of the issued and outstanding Common Shares of the Issuer.

FSD holds 75,003,750 of the Common Shares through its wholly-owned subsidiary, FV Pharma. The Common Shares are held in escrow in accordance with the rules of the Canadian Securities Exchange. Immediately prior to the completion of the Business Combination, FSD did not own or exercise control or direction over any securities of the Issuer.   

FSD holds and controls its Common Shares of the Issuer for investment purposes only and FSD may increase or decrease its beneficial ownership or control over the Common Shares of the Issuer, which it may do, subject to the terms of the escrow arrangements, from time to time, depending on market or other conditions and to the extent deemed advisable in light of its general investment strategy.

This news release is being disseminated as required by National Instrument 62-103 - The Early Warning System and Related Take-Over Bids and Insider Reporting Issues in connection with the anticipated filing of an early warning report (the "Early Warning Report"). A copy of the Early Warning Report will be available on SEDAR under the Issuer's issuer profile at www.sedar.com and can be obtained by contacting the Company as set out below.

SOURCE FSD Pharma Inc.

© Canada Newswire, source Canada Newswire English

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FSD PHARMA INC
03/13FSD PHARMA : Announces New Leadership Appointment and Board Change
BU
03/05FSD PHARMA : Investments Provide Unique Diversification -- CFN Media
AQ
03/01FSD PHARMA : Canntab Enters into Five Year Supply and Loan Agreement with FSD Ph..
AQ
02/28FSD PHARMA : Enters into Five Year Supply and Loan Agreement with Canntab Therap..
BU
02/19FSD PHARMA : Receives Standard Processing License
BU
02/14FSD PHARMA : Provides Update on Operations, Strategy and Leadership
BU
02/12FSD PHARMA : Enters into Supply Agreement with Canntab Therapeutics and World Cl..
BU
02/08FSD PHARMA : responds to and corrects misleading Auxly claims
AQ
02/08FSD PHARMA :  Pharma Responds to and Corrects Misleading Auxly Claims
BU
02/08FSD PHARMA : Fires Newly Hired CEO from GW Pharma and Terminates Auxly Agreement
AQ
More news
Chart FSD PHARMA INC
Duration : Period :
FSD Pharma Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Raza Bokhari Executive Co-Chairman & Chief Executive Officer
Anthony J. Durkacz Co-Chairman
Donal Carroll Chief Financial Officer
Vladimir Klacar Director
Gerald Goldberg Director
Sector and Competitors
1st jan.Capitalization (M$)
FSD PHARMA INC-22.81%0
CANOPY GROWTH CORP62.63%15 250
AURORA CANNABIS INC78.47%9 128
BEIJING TONGRENTANG CO., LTD.9.35%6 140
DONG-E-E-JIAO CO LTD--.--%4 697
HUTCHISON CHINA MEDITECH LIMITED21.29%3 971